Marimed (MRMD) Net Cash Flow Growth (1y) (2013 - 2026)
Marimed (MRMD) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.06 Bn | 20.90 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.43 Bn | 18.62 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.81 Bn | 16.49 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -1,020.00% |
| 10 | Marimed | 25.72 Mn | 17.78 Mn | 15.28 Mn | -1,069.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,069.14% |
| Dec 31, 2025 | 191.30% |
| Sep 30, 2025 | 213.37% |
| Jun 30, 2025 | 78.92% |
| Mar 31, 2025 | -113.75% |
| Dec 31, 2024 | -280.81% |
| Sep 30, 2024 | 70.64% |
| Jun 30, 2024 | 27.56% |
| Mar 31, 2024 | -95.03% |
| Dec 31, 2023 | 200.73% |
| Sep 30, 2023 | -142.97% |
| Jun 30, 2023 | 72.77% |
| Mar 31, 2023 | 213.37% |
| Dec 31, 2022 | -133.54% |
| Sep 30, 2022 | -61.07% |
| Jun 30, 2022 | -607.26% |
| Mar 31, 2022 | -59.40% |
| Dec 31, 2021 | 456.03% |
| Sep 30, 2021 | 10,605.47% |
| Jun 30, 2021 | 939.12% |